Enoblituzumab

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

ET

Key Points: 
  • ET
    ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023.
  • “We expect that 2024 will be an important year for MacroGenics, with multiple pipeline advancements anticipated," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
  • MacroGenics completed enrollment of the TAMARACK Phase 2 study of vobra duo in November 2023.
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2023.
  • Revenue: Total revenue was $10.4 million for the quarter ended September 30, 2023, compared to total revenue of $41.7 million for the quarter ended September 30, 2022.
  • R&D Expenses: Research and development expenses were $30.1 million for the quarter ended September 30, 2023, compared to $48.2 million for the quarter ended September 30, 2022.
  • SG&A Expenses: Selling, general and administrative expenses were $12.4 million for the quarter ended September 30, 2023, compared to $15.4 million for the quarter ended September 30, 2022.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2023.
  • MacroGenics began enrolling the TAMARACK Phase 2 study of vobra duo in patients with mCRPC under an amended protocol during the second quarter.
  • MacroGenics anticipates enrolling a majority of the study patients in 2023 and expects to provide a clinical update in 2024.
  • R&D Expenses: Research and development expenses were $43.2 million for the quarter ended June 30, 2023, compared to $51.7 million for the quarter ended June 30, 2022.

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023

ET

Key Points: 
  • ET
    ROCKVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2023.
  • MacroGenics initiated the Phase 2 portion of the TAMARACK study of vobra duo in patients with mCRPC in late 2022.
  • MacroGenics anticipates commencement of enrollment under the revised protocol beginning in the second quarter of 2023 and expects to provide a clinical update in 2024.
  • R&D Expenses: Research and development expenses were $45.9 million for the quarter ended March 31, 2023, compared to $61.4 million for the quarter ended March 31, 2022.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022

ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June30, 2022.

Key Points: 
  • ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June30, 2022.
  • We made important progress in the second quarter, during which we completed enrollment in a Phase 1/2 dose expansion study of lorigerlimab, a PD-1 CTLA-4 DART molecule.
  • Recent progress and anticipated events in 2022 related to MacroGenics investigational product candidates in clinical development are highlighted below.
  • Revenue for the quarter ended June30, 2022 included MARGENZA net sales of $4.7 million, compared to $3.2million for the quarter ended June30, 2021.

MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

Retrieved on: 
Friday, July 8, 2022

2019 Dec 1, 37(34):3266) and in the context of a risk : benefit analysis, prompted the Companys decision to close the study.

Key Points: 
  • 2019 Dec 1, 37(34):3266) and in the context of a risk : benefit analysis, prompted the Companys decision to close the study.
  • MacroGenics continues to investigate and monitor these events, and an analysis of the data is ongoing.
  • Our top concern in conducting clinical trials is the safety of study participants, saidScott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
  • MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

Retrieved on: 
Tuesday, May 3, 2022

ROCKVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March31, 2022.

Key Points: 
  • ROCKVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March31, 2022.
  • Following a constructive FDA meeting in March 2022, MacroGenics finalized the Phase 2/3 study design of MGC018 in patients with metastatic castration-resistant prostate cancer (mCRPC).
  • R&D Expenses: Research and development expenses were $61.4 million for the quarter ended March31, 2022, compared to $53.1 million for the quarter ended March31, 2021.
  • MacroGenics will host a conference call today at 4:30 p.m. (ET) to discuss financial results for the quarter ended March31, 2022, and provide a corporate update.

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022

Taken together, these data support further development of TJ-C64B towards clinical development subsequently.

Key Points: 
  • Taken together, these data support further development of TJ-C64B towards clinical development subsequently.
  • Enoblituzumab is an investigational Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of immune regulator proteins.
  • B7-H3 is widely expressed by many different tumor types and may play a key role in regulating the immune response to various types of cancer.
  • TJ-C64B is a bispecific antibody simultaneously targeting tumor associated antigen Claudin 6 (CLDN6) and costimulatory molecule 4-1BB for CLDN6+ tumor treatment.

Global Head and Neck Cancer Disease Market Analysis Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022

The "Disease Analysis: Head and Neck Cancer" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Head and Neck Cancer" report has been added to ResearchAndMarkets.com's offering.
  • The report estimated that in 2018, there were 880,700 incident cases of head and neck cancer (HNC) worldwide, and expects that number to increase to 967,000 incident cases by 2027.
  • Though a heterogenous group of diseases, the overwhelming majority (90%) of HNCs are comprised of head and neck squamous cell carcinomas (HNSCCs).
  • Keytruda is also seeking its first approval for nasopharyngeal cancer, as KEYNOTE-122 is evaluating the drug versus standard-of-care chemotherapy for recurrent/metastatic nasopharyngeal cancer.

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

Retrieved on: 
Monday, September 13, 2021

The abstract submitted to ESMO included data as of May 3, 2021, while the final poster will include updated results as of August 16, 2021.

Key Points: 
  • The abstract submitted to ESMO included data as of May 3, 2021, while the final poster will include updated results as of August 16, 2021.
  • The efficacy data and safety cutoff dates for this poster were July 19, 2021 and August 3, 2021, respectively.
  • The abstracts referenced above were submitted to ESMO in May 2021 and are available on the ESMO website.
  • The posters will be available for on-demand viewing on the ESMO website and on the "Events & Presentations" page in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm on or around September 16, 2021.